Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib dose escalation in stable NSCLC
NCT01690390Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2012
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01690390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690390.